Sunday, December 10, 2023
  • Advertise
  • Recruitment
  • Contact
  • Register
  • Login
Irish Pharmacy News
  • News
    BOOTS ANNOUNCES NEW ONLINE PROCESS FOR EMERGENCY CONTRACEPTION SERVICE

    BOOTS ANNOUNCES NEW ONLINE PROCESS FOR EMERGENCY CONTRACEPTION SERVICE

    Groundbreaking National Skin Cancer Service is being blocked by up to two thirds of dermatology departments despite having HSE approved funding and capacity for 20,000 HSE patients in 2023 – Why Is This So?

    Groundbreaking National Skin Cancer Service is being blocked by up to two thirds of dermatology departments despite having HSE approved funding and capacity for 20,000 HSE patients in 2023 – Why Is This So?

    83% of Over-65s Living with a Medical Condition

    83% of Over-65s Living with a Medical Condition

    Fleming Medical Supports Irish Red Cross

    Fleming Medical Supports Irish Red Cross

    Viatris scores victory for Irish charity! 

    Viatris scores victory for Irish charity! 

    New Safety Data Suggests Esketamine Nasal Spray is More Tolerable and Effective Compared to Quetiapine Extended-Release (XR) in Adults with Treatment-resistant Major Depressive Disorder1,2

    New Safety Data Suggests Esketamine Nasal Spray is More Tolerable and Effective Compared to Quetiapine Extended-Release (XR) in Adults with Treatment-resistant Major Depressive Disorder1,2

    Fleming Medical Supporting Aspiring Athletes with Team Physiologix

    Fleming Medical Supporting Aspiring Athletes with Team Physiologix

    Sinéad Crowther of Soothing Solutions announced as HPSU ‘Founder of the Year 2023’ at Enterprise Ireland awards

    Sinéad Crowther of Soothing Solutions announced as HPSU ‘Founder of the Year 2023’ at Enterprise Ireland awards

    MULLINGAR HOSTS NATIONAL EVENT HONOURING ORGAN DONORS 

    MULLINGAR HOSTS NATIONAL EVENT HONOURING ORGAN DONORS 

  • Learning
    • CPD
    • Features
    • Team Training
    • Research
  • Magazines
  • OTC
    • Product News
    • Profiles
  • Awards
    • Irish Pharmacy Awards 2022
    • OTC Awards
  • HPN
No Result
View All Result
  • News
    BOOTS ANNOUNCES NEW ONLINE PROCESS FOR EMERGENCY CONTRACEPTION SERVICE

    BOOTS ANNOUNCES NEW ONLINE PROCESS FOR EMERGENCY CONTRACEPTION SERVICE

    Groundbreaking National Skin Cancer Service is being blocked by up to two thirds of dermatology departments despite having HSE approved funding and capacity for 20,000 HSE patients in 2023 – Why Is This So?

    Groundbreaking National Skin Cancer Service is being blocked by up to two thirds of dermatology departments despite having HSE approved funding and capacity for 20,000 HSE patients in 2023 – Why Is This So?

    83% of Over-65s Living with a Medical Condition

    83% of Over-65s Living with a Medical Condition

    Fleming Medical Supports Irish Red Cross

    Fleming Medical Supports Irish Red Cross

    Viatris scores victory for Irish charity! 

    Viatris scores victory for Irish charity! 

    New Safety Data Suggests Esketamine Nasal Spray is More Tolerable and Effective Compared to Quetiapine Extended-Release (XR) in Adults with Treatment-resistant Major Depressive Disorder1,2

    New Safety Data Suggests Esketamine Nasal Spray is More Tolerable and Effective Compared to Quetiapine Extended-Release (XR) in Adults with Treatment-resistant Major Depressive Disorder1,2

    Fleming Medical Supporting Aspiring Athletes with Team Physiologix

    Fleming Medical Supporting Aspiring Athletes with Team Physiologix

    Sinéad Crowther of Soothing Solutions announced as HPSU ‘Founder of the Year 2023’ at Enterprise Ireland awards

    Sinéad Crowther of Soothing Solutions announced as HPSU ‘Founder of the Year 2023’ at Enterprise Ireland awards

    MULLINGAR HOSTS NATIONAL EVENT HONOURING ORGAN DONORS 

    MULLINGAR HOSTS NATIONAL EVENT HONOURING ORGAN DONORS 

  • Learning
    • CPD
    • Features
    • Team Training
    • Research
  • Magazines
  • OTC
    • Product News
    • Profiles
  • Awards
    • Irish Pharmacy Awards 2022
    • OTC Awards
  • HPN
No Result
View All Result
Irish Pharmacy News
Home News

Erleada®▼(apalutamide) approved for reimbursement in Ireland for the Treatment of Patients with Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

Aoife by Aoife
18 April 2023
in News
0
Erleada®▼(apalutamide) approved for reimbursement in Ireland for the Treatment of Patients with Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

Janssen, the Pharmaceutical Companies of Johnson & Johnson, announced today that Erleada®▼(apalutamide) has been granted reimbursement in Ireland for the treatment of adult men with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (ADT).

Professor Paul Donnellan, Consultant Medical Oncologist, Galway University Hospital, Mayo University Hospital and Galway Clinic said: “For patients with newly-diagnosed metastatic prostate cancer, delaying disease-progression and improving survival are paramount. For many years, suppressing androgen production has been the mainstay of treatment. It has been proven that adding an oral agent to this treatment, significantly improves both time to progression and overall survival, without any negative impact on Quality of Life (QoL).  This represents a significant advance for all patients with advanced prostate cancer.”

Dr Thorsten Giesecke, General Manager, Commercial Business, Janssen Sciences Ireland UC, said:“Janssen is committed to improving prognosis and outcomes for men across the prostate cancer continuum with a growing portfolio and pipeline of therapeutics spanning all modalities and stages of the disease. Today’s reimbursement of apalutamide for the treatment of mHSPC represents an important, positive step on that journey.”

Data from the Phase III TITAN study assessed the addition of apalutamide to ADT in a broad range of patients with mHSPC, regardless of disease volume, prior treatment with docetaxel or staging at initial diagnosis.1 The dual primary endpoints of the study were overall survival (OS) and radiographic progression-free survival (rPFS).1,2 Data from the interim analysis2 showed that at 24 months, apalutamide plus ADT significantly improved OS compared to placebo plus ADT with a 33 percent reduction in the risk of death (HR=0.67; 95% CI, 0.51-0.89; p=0.005).2 The interim analysis also revealed that apalutamide plus ADT also significantly improved rPFS compared to placebo plus ADT with a 52 percent reduction in risk of radiographic progression or death compared to placebo plus ADT (HR=0.48; 95% CI, 0.39-0.60; p<0.001).2 

The final analysis of TITAN and its long-term results demonstrate that apalutamide plus ADT consistently provides significant improvements in OS and delays onset of progression.1 The OS rates at 48 months were 65.1% and 51.8% for apalutamide- and placebo-treated patients, respectively.1

The safety profile observed in the TITAN study for apalutamide plus ADT was consistent with that described in previous studies.2,3 In the final analysis, the overall incidence of any treatment-emergent adverse events (TEAEs) was similar between treatment groups  and to those reported previously.1  The most common treatment-related AEs (adverse events) related to treatment with apalutamide were rash and fatigue.1 There were no treatment-related deaths.1

Previous Post

Achieve ‘the unachievable’ with Great Lengths Balayage Blends Balyage Blends will return to Dublin on July 31st

Next Post

Making decisions about infertility treatment

Next Post
Making decisions about infertility treatment

Making decisions about infertility treatment

The Two Biggest issues in the Irish Pharmacy Sector Today

The Two Biggest issues in the Irish Pharmacy Sector Today

4 December 2023
Overactive Bladder: Diagnosis and Treatment

Overactive Bladder: Diagnosis and Treatment

4 December 2023
Would you like your children to have a pension worth €2,000,000 when they turn 50?

Would you like your children to have a pension worth €2,000,000 when they turn 50?

4 December 2023

RECOMMENDED NEWS

Think Sepsis! World Sepsis Day 13 September

3 years ago
Winner – Community Pharmacy Technician of the Year Award

Winner – JPA Brenson Lawlor Young Pharmacist of the Year Award

2 years ago
Clane Pharmacist Jonathon Morrissey Shortlisted for The People’s Pharmacist of the Year 2021

Clane Pharmacist Jonathon Morrissey Shortlisted for The People’s Pharmacist of the Year 2021

2 years ago
Gain Control of Resources With Time And Attendance Tracking

Gain Control of Resources With Time And Attendance Tracking

2 years ago
Tweets by Irish_PharmNews

Quick links

  • About
  • Advertise
  • Careers
  • Contact

Follow us on social media:

Other info

  • Contact
  • Register for Digital Magazines
  • Privacy Policy
  • About
  • Advertise
  • Careers
  • Contact

© 2020

No Result
View All Result
  • News
  • Learning
  • Other
    • Conferencing
    • Developments
    • Product News
    • Profiles
    • Research
  • Digital Magazines
  • Awards

© 2020

  • Login

    Forgot password?

    Register

    Registration confirmation will be emailed to you.

    Login | Forgot password?

    Reset Password

    Please enter your username or email address. You will receive a link to create a new password via email.

    Login

Login

Forgotten Password?

Lost your password?
| Back to Login

This website is only for the eyes of medical professionals. Are you a medical professional?